Intelligent Bio Solutions (INBS)

Executive Summary

Intelligent Bio Solutions (INBS) is a medical technology company pioneering non-invasive diagnostics through its flagship Intelligent Fingerprinting Drug Screening System, which uses fingerprint sweat analysis to detect drugs of abuse. This pain-free, dignified alternative to urine or blood testing addresses a significant unmet need in workplace, forensic, and clinical settings, where sample collection compliance and dignity are critical. The company also develops wearable monitoring devices for continuous biomarker tracking. With a growing emphasis on decentralized testing and employee wellness, INBS is well-positioned to disrupt the multi-billion-dollar drug testing market. The company is publicly traded (NASDAQ: INBS) and based in New York, with a valuation of approximately $5 million. As of mid-2026, INBS is actively commercializing its sweat-based drug screening platform, targeting initial customers in workplace safety and law enforcement. The company is pursuing FDA 510(k) clearance to expand into clinical diagnostics, which could unlock larger reimbursement-backed markets. Additionally, INBS is developing a continuous health monitoring wearable that leverages the same sweat analysis technology for metabolic and hydration tracking. Key near-term catalysts include regulatory milestones, strategic distribution partnerships, and product launches. While the company faces execution risk and limited financial resources, its novel platform and first-mover advantage in non-invasive drug testing provide significant upside if commercial traction accelerates.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for Intelligent Fingerprinting Drug Screening System70% success
• Q4 2026Strategic partnership with major workplace drug testing provider60% success
• H1 2027Launch of wearable sweat monitoring device50% success